Heart failure is one of the most prevalent and life-threatening cardiovascular conditions worldwide, characterized by the heart’s inability to pump sufficient blood to meet the body’s needs. This article explores recent advancements in the diagnosis and treatment of heart failure, focusing on innovative pharmacological agents, device-based therapies, and regenerative approaches. Modern medications such as angiotensin receptor–neprilysin inhibitors (ARNIs) and sodium–glucose cotransporter-2 (SGLT2) inhibitors have transformed conventional treatment strategies, significantly reducing mortality and hospitalization rates. Moreover, novel technologies including cardiac resynchronization therapy, ventricular assist devices, and artificial intelligence–based monitoring systems have improved clinical outcomes and patient quality of life. The article also reviews ongoing research into gene therapy and stem cell–based cardiac regeneration, highlighting the potential for future breakthroughs in restoring myocardial function. Through a multidisciplinary approach that combines pharmacologic innovation, technological advancement, and personalized care, the management of heart failure is entering a new era of precision and effectiveness.

Heart failure, pharmacological treatment, SGLT2 inhibitors, ARNIs, cardiac resynchronization therapy, ventricular assist devices, gene therapy, regenerative medicine, artificial intelligence, cardiovascular health.

McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., ... & Chioncel, O. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 42(36), 3599–3726. https://doi.org/10.1093/eurheartj/ehab368

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., ... & Yancy, C. W. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 79(17), e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012

Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., ... & Zannad, F. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine, 383(15), 1413–1424. https://doi.org/10.1056/NEJMoa2022190

McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., ... & DeMets, D. L. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995–2008. https://doi.org/10.1056/NEJMoa1911303

Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., ... & Malik, F. I. (2021). Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction. Nature Reviews Cardiology, 18(12), 881–892. https://doi.org/10.1038/s41569-021-00594-5

Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., ... & Wilkoff, B. L. (2017). 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 70(6), 776–803.

Madonna, R., Van Laake, L. W., Botker, H. E., Davidson, S. M., De Caterina, R., Engel, F. B., ... & Ferdinandy, P. (2016). Stem cells and exosomes in the treatment of heart failure. Circulation Research, 119(8), 1100–1122. https://doi.org/10.1161/CIRCRESAHA.116.307708

Truby, L. K., & Rogers, J. G. (2020). Advanced heart failure: Epidemiology, diagnosis, and therapeutic approaches. Journal of the American College of Cardiology, 75(16), 2003–2016. https://doi.org/10.1016/j.jacc.2020.03.022

Gorter, T. M., van Veldhuisen, D. J., Bauersachs, J., Borlaug, B. A., Celutkiene, J., Coats, A. J. S., ... & Lam, C. S. P. (2023). Heart failure with preserved ejection fraction: Recent advances and future directions. European Heart Journal, 44(8), 679–691. https://doi.org/10.1093/eurheartj/ehad022

Wang, T. J., & Larson, M. G. (2022). Artificial intelligence in heart failure management. Nature Medicine, 28(9), 1782–1794. https://doi.org/10.1038/s41591-022-01944-z